Lamyrox Tablet 150mg

Country: Malaysia

Bahasa: Inggeris

Sumber: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Bahan aktif:

LAMIVUDINE

Boleh didapati daripada:

PHARMANIAGA MANUFACTURING BERHAD

INN (Nama Antarabangsa):

LAMIVUDINE

Unit dalam pakej:

60tablet Tablets; 60tablet Tablets

Dikeluarkan oleh:

PHARMANIAGA MANUFACTURING BERHAD

Risalah maklumat

_Consumer Medication Information Leaflet (RiMUP) _
LAMYROX TABLET 150MG
Lamivudine (150mg)
_ _
1
WHAT IS IN THIS LEAFLET
1.
What
Lamyrox
Tablet
150mg is used for
2.
How
Lamyrox
Tablet
150mg works
3.
Before
you
use
Lamyrox
Tablet 150mg
4.
How to use Lamyrox Tablet
150mg
5.
While
you
are
using
Lamyrox Tablet 150mg
6.
Side effects
7.
Storage
and
disposal
of
Lamyrox Tablet 150mg
8.
Product description
9.
Manufacturer
and
Product
Registration Holder
10.
Date of revision
WHAT LAMYROX TABLET 150MG
IS USED FOR
Lamyrox Tablet 150mg is used
with
other
antiretroviral
medicines,
to
slow
down
the
progression
of
Human
Immunodeficiency Virus (HIV)
infection in adults and children.
HIV
can
lead
to
Acquired
Immune
Deficiency
Syndrome
(AIDS)
and
other
related
illnesses.
HOW LAMYROX TABLET 150MG
WORKS
Treatment with Lamyrox Tablet
150mg can hinder the growth of
human immunodeficiency virus.
In
this
way
it
stops
ongoing
damage to the body’s immune
system (which fights infection)
by stopping production of new
viruses.
BEFORE
YOU
USE
LAMYROX
TABLET 150MG
_-When you must not use it _
Do
not
take
Lamyrox
Tablet
150mg if you have an allergy to
any
medicine
containing
lamivudine or any of the other
ingredient (listed at the end of the
leaflet).
Do not take this medicine if you
are pregnant or trying to become
pregnant, without first talking to
your doctor. Your doctor should
discuss with you the risks and
benefits of taking these tablets if
you are pregnant.
Breastfeeding
is
not
recommended
while
you
are
taking
Lamyrox Tablet 150mg
because:

lamivudine
may
enter
the
breast
milk
and
there
is
a
possibility your baby may be
affected

there is a risk of passing the
HIV infection to your baby.
Do not take this medicine after
the expiry date printed on the
pack
or
if
the
packaging
is
damaged
or
shows
signs
of
tampering. If it has expired or is
damaged,
return
it
to
your
pharmacist for disposal.
If
you
have
certain
health
conditions,
your
doctor
may
advise that you take lower dose
of Lamyrox Tablet 150mg.
If you are not sure whether you

Ciri produk

LAMYROX TABLET 150MG
DESCRIPTION
White to off white, biconvex, oval shaped, film coated tablet with
Pharmaniaga icon on one side and plain on the other.
COMPOSITION
Each film-coated tablet contains Lamivudine 150 mg
PHARMACODYNAMICS
Lamivudine is a potent, selective inhibitor of HIV-1 and HIV-2
replication
_in vitro_
. It is also active against zidovudine-resistant
clinical isolates of HIV.
Lamivudine is metabolised intracellularly to the 5'-triphosphate, the
active moiety, which has an intra-cellular half-life of 16-19
hours. Lamivudine 5'- triphosphate is a weak inhibitor of the RNA and
DNA dependant activities of HIV reverse transcriptase, its
main mode of action is as a chain terminator of HIV reverse
transcription.
Lamivudine does not interfere with cellular deoxynucleotide metabolism
and has little effect on mammalian cell and mitochondrial
DNA content.
_In vitro_
, lamivudine demonstrates low cytotoxicity to peripheral blood
lymphocytes, to established lymphocyte and monocyte-
macrophage cell lines, and to a variety of bone marrow progenitor
cells
_in vitro_
. Lamivudine therefore has,
_in vitro_
, a high
therapeutic index.
HIV-1 resistance to lamivudine involves the development of a M184V
amino acid change close to the active site of the viral reverse
transcriptase (RT). This variant arises both
_in vitro_
and in HIV-1 infected patients treated with lamivudine-containing
antiretroviral
therapy. M184V mutants display greatly reduced susceptibility to
lamivudine and show diminished viral replicative capacity
_in _
_vitro_
.
_In vitro_
studies indicate that zidovudine-resistant virus isolates can become
zidovudine sensitive when they simultaneously
acquire resistance to lamivudine. The clinical relevance of such
findings remains, however, not well defined.
Cross-resistance conferred by the M184V RT is limited within the
nucleoside inhibitor class of antiretroviral agents. Zidovudine
and stavudine maintain their antiretroviral activities against
lamivudine-resistant HIV-1. Abacavir maintains its antiretrovira